National Cancer Institute
U.S. National Institutes of Health | www.cancer.gov

NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
NCI Drug Dictionary
Page Options
Print This Page
Quick Links
Director's Corner
Updates from the Director

Dictionary of Cancer Terms
Cancer-related terms

NCI Drug Dictionary
Definitions, names, and links

Funding Opportunities
Research and training

NCI Publications
Order/download free booklets

Advisory Boards and Groups
Information, meetings, reports

Science Serving People
Learn more about NCI

Español
Información en español
NCI Highlights
Virtual and Standard Colonoscopy Both Accurate

NCI Responds to Hurricanes

The Nation's Investment in Cancer Research FY 2009

Cancer Trends Progress Report: 2007 Update

Past Highlights
You CAN Quit Smoking Now!
Search for
# A B C D E F G H I J K L M N O P Q R S T U V W X Y Z All

pneumococcal polyvalent vaccine
An polyvalent vaccine used to prevent infection by the bacterium Streptococcus pneumoniae. Pneumococcal polyvalent vaccine contains higly purified capsular antigens from the 23 most prevalent or invasive pneumococcal types of Streptococcus pneumoniae to ensure cross-protection. Following vaccination, protective capsular type-specific antibody levels typically develop by the third week; serotype-specific antibody levels generally decline after 5-10 years. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

US brand names:Pneumovax 23
Pnu-Imune 23



Previous:Platinol-AQ, plerixafor, plevitrexed, plicamycin, plitidepsin
Next:Pneumovax 23, pNGVL3-hICD vaccine, pNGVL4a-Sig/E7(detox)/HSP70 DNA vaccine, PNP-expressing ovine atadenovirus FP253, Pnu-Imune 23

A Service of the National Cancer Institute
Department of Health and Human Services National Institutes of Health USA.gov